Genetic Landscape of Male Breast Cancer

Male breast cancer (MBC) is now considered molecularly different from female breast cancer (FBC). Evidence from studies indicates that common genetic and epigenetic features of FBC are not shared with those diagnosed in men. Genetic predisposition is likely to play a significant role in the tumorige...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2021-07, Vol.13 (14), p.3535
Hauptverfasser: Campos, Fernando Augusto Batista, Rouleau, Etienne, Torrezan, Giovana Tardin, Carraro, Dirce Maria, Casali da Rocha, José Claudio, Mantovani, Higor Kassouf, da Silva, Leonardo Roberto, Osório, Cynthia Aparecida Bueno de Toledo, Moraes Sanches, Solange, Caputo, Sandrine M, Santana Dos Santos, Elizabeth
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Male breast cancer (MBC) is now considered molecularly different from female breast cancer (FBC). Evidence from studies indicates that common genetic and epigenetic features of FBC are not shared with those diagnosed in men. Genetic predisposition is likely to play a significant role in the tumorigenesis of this rare disease. Inherited germline variants in and account for around 2% and 10% of MBC cases, respectively, and the lifetime risk of breast cancer for men harboring and mutations is 1.2% and 6.8%. As for FBC, pathogenic mutations in other breast cancer genes have also been recently associated with an increased risk of MBC, such as and mutations. However, while multigene germline panels have been extensively performed for BC female patients, the rarity of MBC has resulted in limited data to allow the understanding of the magnitude of risk and the contribution of recently identified moderate penetrance genes of FBC for MBC predisposition. This review gathers available data about the germline genetic landscape of men affected by breast cancer, estimated risk associated with these genetic variants, and current guidelines for clinical management.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13143535